The stock has a market capitalization of Rs 151 crore and the stock is trading at a PE multiple of 8.79.
Samrat Pharmachem Limited was incorporated on June 16e, 1992 at Ankleshwar in the State of Gujarat in India by Mr. Lalit Mehta and Mr. Rajesh Mehta. The company started its operations by acquiring a factory land at Ankleshwar. The founders of the company Mr. Lalit Mehta and Mr. Rajesh Mehta decided to focus on “IODINEas a key ingredient for all their products with a vision to become the king of iodine chemistry.
The company decided to accelerate its growth by adding new products and acquiring more land in addition to its existing configuration. The company has become a major supplier of iodine derivatives in the Indian and overseas market.
With profitable manufacturing capabilities and loyal customers, the company has also entered new industries such as the manufacturing segment of salt, animal feed, textiles and tire cords. Today, Samrat Pharmachem has grown into a knowledge-based company that manufactures pharmaceutical ingredients. It is R&D driven and has a multi-product portfolio with a state-of-the-art plant and manufacturing facility in Ankleshwar.
The stock has jumped over 100% in the past year and it has proven to be a multibaggermeanwhile, the performance of the past three years would leave you spellbound as the stock has generated eye-popping returns of 671%.
The stock has released its blockbuster financial results for the quarter ended June 30, 2022.
Here are some of the main highlights for T1FY23:
The company delivered a much improved quarterly performance in the first quarter of FY23 by recording healthy and astonishing growth in both revenue and net income.
Total operating revenue for the quarter ended June 2022 was Rs 86.51 crore, up 83% year on year, while net profit soared to Rs 9.37 crore. rupees with a staggering growth of 882% on an annual basis. The company’s net profit also increased sequentially from Rs 6.99 crore to Rs 9.37 crore, an increase of almost 34%.
The stock has a market cap of Rs 151 crore and the stock is trading at a PE multiple of 8.79.
The stock’s 52-week high stands at Rs 578 and is currently trading around Rs 489, which translates to a discount of Rs 15% from its 52-week high.
Samrat Pharmachem exports its finished products worldwide. Their customers include high-end multinational corporations with multiple facilities approved by major regulatory bodies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and l Brazilian ANVISA, Samrat Pharmachem uses in-house R&D as well as a team of technical experts in the field of iodine to offer the widest range of derivatives to its customers.